KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accounts Payables (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Accounts Payables for 7 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 45.13% to $19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.4 million through Dec 2025, up 45.13% year-over-year, with the annual reading at $19.4 million for FY2025, 45.13% up from the prior year.
  • Accounts Payables hit $19.4 million in Q4 2025 for Royalty Pharma, down from $41.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $41.4 million in Q3 2025 to a low of $5.6 million in Q4 2021.
  • Historically, Accounts Payables has averaged $15.3 million across 5 years, with a median of $12.8 million in 2022.
  • Biggest five-year swings in Accounts Payables: crashed 72.67% in 2021 and later surged 303.1% in 2024.
  • Year by year, Accounts Payables stood at $5.6 million in 2021, then skyrocketed by 40.68% to $7.9 million in 2022, then soared by 91.82% to $15.2 million in 2023, then decreased by 11.84% to $13.4 million in 2024, then surged by 45.13% to $19.4 million in 2025.
  • Business Quant data shows Accounts Payables for RPRX at $19.4 million in Q4 2025, $41.4 million in Q3 2025, and $20.2 million in Q2 2025.